Evaluation of antioxidant potential of Emblica officinalis and Murraya koenigii and their role in modulation of cognitive function in diabetic rats


  • Tarun Arora Department of Pharmacology, Lady Hardinge Medical College, New Delhi, India
  • Rudhra P. Kadali Department of Pharmacology, Lady Hardinge Medical College, New Delhi, India
  • Dinesh K. Prasad Department of Pharmacology, University College of Medical Sciences, New Delhi, India




Emblica officinalis, Murraya koenigii, Oxidative stress, Cognitive decline, Diabetes


Background: Hyperglycaemia and hyperlipidaemia seen in diabetes mellitus result in oxidative stress and pose significant risk of cognitive decline that may lead to Alzheimer’s disease. Approved anti-diabetic drugs have so far failed to demonstrate anti-oxidant and anti-hyperlipidemic activity, apart from saroglitazar. Therefore, this study was done to find a suitable anti-diabetic drug that possesses anti-hyperglycaemic, anti-oxidant and anti-hyperlipidemic activities and can reverse cognitive decline.

Methods: Emblica officinalis (250 mg/kg, p.o. and 500 mg/kg, p.o.) and Murraya koenigii (250 mg/kg, p.o. and 500 mg/kg, p.o.) were chosen to study these activities in Wistar rats. Diabetes was induced by single intraperitoneal injection of streptozotocin [STZ] (50 mg/kg). Fasting blood glucose levels and lipid profile were measured on day 1 and day 30 of the experiment. Cognitive function was assessed by measuring transfer latency (TL) on elevated plus maze, step-down latency (SDL) on passive avoidance apparatus and retention latency (RL) and quadrant time (QT) in Morris water maze. Oxidative stress was assessed at end of study by measuring brain MDA and GSH levels. Cholinergic marker of cognition, AChE was measured in brain at end of study.

Results: Both E. officinalis and M. koenigii showed dose dependent anti-hyperglycemic, anti-hyperlipidemic and anti-oxidant effects in diabetic rats with 500 mg/kg dose showing significantly higher effect. Both 250 mg/kg and 500 mg/kg dose of E. officinalis and M. koenigii partially reversed cognitive decline in diabetic rats by day 30.

Conclusions: 500 mg/kg p.o. dose of E. officinalis or M. koenigii has potential to reverse cognitive decline in diabetic patients.



Ernest A, Peter S, Earl D. An update on the etiology and epidemiology on Diabetes mellitus. Ann N Y Acad Sci. 2006;1084:1-29.

Rao KB, AppaRao CH. Hypoglycemic and antihyperglycemic activity of alternifolium (Wt) Walp seed extract in normal and diabetic rats. Phytomed. 2001;8:88-93.

Upathaya V, Pandya K. Ayurvedic approach to diabetes mellitus and its management by indigenous resources, Bajaj JS (Ed.) Diabetes mellitus in developed countries. New delhi Inter Print. 1984;16:375-77.

Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008;7:184-90.

Jamwal KS, Sharma IP, Chopra CL. Pharmacological investigation on the fruits of Emblica officinalis. J Sci Ind Res. 1959;18:180-1.

Jayashri S, Jolly CI. Phytochemical, antibacterial and pharmacological investigations on Momordicachirantia and Emblica officinalis. Indian J Pharm Sci. 1993;1:6-13.

Achilya GS, Wadodkar SG, Dorle AK. Evaluation of hepatoprotective effect of Amalkadi Ghrita against carbon tetrachloride-induced hepatic damage in rats. J Ethnopharmacol. 2004;90:2-3.

Jose JK, Kuttan R. Hepatoprotective activity of Emblica officinalis and Chyavanaprash. J Ethnopharmacol. 2000;72:135-40.

Thakur CP, Mandal K. Effect of Emblica officinalis on cholesterol induced atherosclerosis in rabbits. J Med Res. 1984;79:142-6.

Vinuthan MK, Kumar GV, Ravindra JP, Narayana JK. Effect of extracts of Murraya koenigii leaves on the levels of blood glucose and plasma insulin in alloxan-induced diabetic rats. Indian J Physiol Pharmacol. 2004;48(3):348–52.

Ardura J, Gutierrez R, Andresn J, Agapito T. Emergence and evolution of the circadian rhythm of melatonin in children. Hormone Res. 2002;59:66–72.

Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter R. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J. 1993;1:57-60.

Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disorders. 2011;41:175-84.

Otsyula M, King MS, Ketcham TG, Sanders RA, Watkins JB. Oxidative stress in rats after 60 days of hypergalactosemia or hyperglycemia. Int J Toxicol. 2003;22:423-7.

Inouye M, Mio T, Sumino K. Link between glycation and lipoxidation in red blood cells in diabetes. Clin Chim Acta.1999;285:35–44.

S Roriz-Filho J, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, et al. (Pre)diabetes, brain aging, and cognition. Biochem Biophys Acta. 2009;1792:432-43.

Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab. 2006;32:403-14.

Manschot SM, Biessels GJ, Cameron NE, Cootter MA, Kamal A, Kappellle LJ, et al. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res. 2003;966:274-82.

Tuzcu M, Baydas G. Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur J Pharmacol. 2006;537:106-10.

Barbalho SM, Damasceno DC, Spada AP, Palhares M, Martuchi KA, Oshiiwa M, et al. Evaluation of glycemic and lipid profile of offspring of diabetic Wistar rats treated with Malpighia emarginata juice. Exp Diabetes Res. 2011;2011:173647.

Bhaskar VH, Ajay SS. Evaluation of antihperglycemic activity of extracts of Calotropis procera (Ait.) R.Br on streptozotocin induced diabetic rats. Global J Pharmacol. 2009;3:95-8.

Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000;23:542-9.

Biessels GJ, Hiede LP, Kamal A. Ageing and diabetes: implications of brain function. Eur J Pharmacol. 2002;441:1-14.

Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci. 2005;6:48-56.

Sanchez-Chavez G, Salceda R. Effect of streptozotocin-induced diabetes on activities of cholinestereases in the rat retina. IUBMB life. 2000;49:283-7.

Schmatz R, Mazzanati CM, Spanevello R, Stefanello N, Gutierres J, Correa M, et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2009;610:42-8.

Kuhad A, Chopra K. Effect of sesamol on diabetes-associated cognitive decline in rats. Exp Brain Res. 2008;185:411-20.

Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol. 2007;576:34-42.




How to Cite

Arora, T., Kadali, R. P., & Prasad, D. K. (2019). Evaluation of antioxidant potential of Emblica officinalis and Murraya koenigii and their role in modulation of cognitive function in diabetic rats. International Journal of Basic & Clinical Pharmacology, 8(9), 2080–2091. https://doi.org/10.18203/2319-2003.ijbcp20194120



Original Research Articles